Elixigen

CompanySouth Korea

Elixigen develops one asset, in phase 2 (NG101 in wet age-related macular degeneration). Mostly gene therapy; based in South Korea.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1
  • NG101

    Phase 2, Gene therapy, wet age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1
  • Similar companies2

Intelligence